STAMFORD, Conn., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced that Joshua H. Bilenker, M.D., Chief Executive Officer, will present a corporate overview at several upcoming conferences.
Details of the conferences are as follows:
- Stifel 2014 Healthcare Conference, November 19 at 11:30 AM, New York Palace Hotel, New York, NY
- Piper Jaffray 26th Annual Healthcare Conference, December 2 at 9:00 AM, New York Palace Hotel, New York, NY
- Oppenheimer 25th Annual Healthcare Conference, December 11 at 1:35 PM, Crowne Plaza Hotel, New York, NY
Webcast links for all presentations can be found at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo's development approach translates key scientific insights relating to the oncogenic drivers of cancer into drugs that are potent and highly selective for their intended targets. This approach is intended to allow for the development of drugs with a high probability of clinical success while reducing the time, costs and risks of drug development. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com.
|Jacob S. Van Naarden|
|Vice President, Corporate Development and Strategy|
|The Trout Group, LLC|
|MacDougall Biomedical Communications|